Advances in chronic obstructive pulmonary disease;Novedades en la enfermedad pulmonar obstructiva crónica

Archivos de Bronconeumologia

Volumn 45, Issue SUPLL.3, 2009, Pages 9-13

  Jiménez, Belén Arnalich ^a   Pumarega, Irene Cano ^b   Ausiró, Anna Mola ^c   Alonso, José Luis Izquierdo ^a  

^a HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^b HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

COPD; Diagnosis; Systemic involvement; Treatment

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID;

AIRWAY OBSTRUCTION; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; ENDOCRINE DISEASE; FORCED EXPIRATORY VOLUME; HUMAN; INDIVIDUALIZATION; INFLAMMATION; MEDICAL RESEARCH; MORTALITY; MUSCLE DISEASE; NEUROLOGIC DISEASE; NUTRITIONAL DEFICIENCY; PATHOPHYSIOLOGY; PATIENT CARE; QUALITY OF LIFE; QUESTIONNAIRE; RESPIRATORY TRACT INFECTION; SPIROMETRY; SURVIVAL RATE; THORAX RADIOGRAPHY;

ALGORITHMS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 72049121475     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S0300-2896(09)72852-2     Document Type: Article

References (34)

1. Report of the conclusions of CIBA guest symposium: terminology, defi nitions and classifi cation of chronic obstructive pulmonary emphysema and related conditions. Thorax. 1959;14:286-99.
2. American Thoracic Society. Definitions and classification of chronic bronchitis, asthma and pulmonary emphysema. Am Rev Respir Dis 85 (1962) 762-768
3. Thurlberck W.M. Aspects of chronic airflow obstruction. Chest 72 (1977) 341-349
4. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., et al. Global strategy for the diagnosis, management and prevention of COPD. GOLD executive Summary. Am J Respir Crit Care Med 176 (2007) 532-555
5. Peces-Barba G., Barberá J.A., Agustí A., Casanova C., Casas A., Izquierdo J.L., et al. Guía Clínica SEPAR-ALAT de diagnóstico y tratamiento de la EPOC. Arch Bronconeumol 44 (2008) 271-281
6. Anthonisen N.R., and Wright E.C. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 133 (1986) 814-819
7. Tashkin D.P., Celli B., Decramer M., Liu D., Burkhart D., Cassino C., et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 31 (2008) 742-750
8. Soriano J.B., and Mannino D.M. Reversing concepts on COPD irreversibility. Eur Respir J 31 (2008) 695-696
9. Hardie J.A., Buist A.S., Vollmer W.M., Ellingsen I., Bakke P.S., and Morkve O. Risk of over diagnosis of COP in asymptomatic elderly never-smokers. Eur Respir J 20 (2002) 1117-1122
10. Izquierdo J.L. Enfermedad pulmonar obstructiva crónica: conceptos a revisar. Medicina Respiratoria 1 (2008) 13-20
11. De Miguel J., Izquierdo J.L., Molina J., Rodríguez J.M., De Lucas P., and Gaspar G. Fiabilidad del diagnóstico de la EPOC en atención primaria y neumología en España. Factores predictivos. Arch Bronconeumol 39 (2003) 203-208
12. Miravitlles M., De la Roza C., Naberan K., Lamban M., Gobartt E., Martín A., et al. Problemas con el diagnóstico de la EPOC en atención primaria. Arch Bronconeumol 42 (2006) 3-8
13. Izquierdo J.L., Rodríguez J.M., de Lucas P., Martín Centeno A., and Gobartt E. ¿Ha cambiado el manejo de la EPOC en España? Resultados de un estudio multicéntrico comunitario (VICE). Rev Clin Esp 208 (2008) 18-25
14. Guyatt G.H., Berman L.B., Townsend M., Pugsley S.O., and Chambers L.W. A measure of quality of life for clinical trials in chronic lung disease. Thorax 42 (1998) 773-778
15. Güell R., Casan P., Sangenís M., Morante F., Belda J., and Guyatt G.H. Quality of life in patients with chronic respiratory disease: the Spanish version of the Chronic Respiratory Questionnaire (CRQ). Eur Respir J 11 (1998) 55-60
16. Celli B.R., Cote C.G., Marín J.M., Casanova C., Montes de Oca M., Méndez R.A., et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350 (2004) 1005-1012
17. Soler-Cataluña J.J., Martínez-García M.A., Román-Sánchez P., Salcedo E., Navarro M., and Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60 (2005) 925-931
18. García-Rio F., Lores V., and Rojo B. Evaluación funcional respiratoria (obstrucción y atrapamiento). Arch Bronconeumol 43 Supl 3 (2007) S8-S14
19. Izquierdo J.L. Nuevos parámetros clínicos en la EPOC. Arch Bronconeumol 44 Supl 2 (2008) 4-10
20. Gelb A.F., Schein M., Kuei J., Tashkin D.P., Müller N.L., Hogg J.C., et al. Limited contribution of emphysema in advanced chronic obstructive pulmonary disease. Am Rev Respir Dis 147 (1993) 1157-1161
21. Wouters EFM, Schols AMWJ, Celli B. Systemic effects of chronic obstructive pulmonary disease. En: Siafalas NM, editor. Management of chronic obstructive pulmonary disease. European Respiratory Society. Eur Respir Mon. 2006;38:224-41.
22. Wouters E.F.M., Creutzberg E.C., and Schols A.M.W.J. Systemic effects in COPD. Chest 121 (2002) 127-130
23. Wouters E.F.M., Groenewegen K.H., Dentener M.A., and Vernooy J.H.J. Systemic inflammation in chronic obstructive pulmonary disease. The role of exacerbations. Proc Am Thorac Soc 4 (2007) 626-634
24. Gea J., and Barreiro E. Actualización en los mecanismos de disfunción muscular en la EPOC. Arch Bronconeumol 44 (2008) 328-337
25. Jagoe R.T., and Encelen M.P.K.J. Muscle wasting and changes in muscle protein metabolism in chronic obstructive pulmonary disease. Eur Respir J 22 Suppl 46 (2003) S52-S63
26. Falk J.A., Kadiev S., Criner G.J., Scharf S.M., Minai O.A., and Diaz P. Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 5 (2008) 543-548
27. Sin D.D., and Man P. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potencial role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107 (2003) 1514-1519
28. Sin D.D., and Man P. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2 (2005) 8-11
29. Decramer M., De Benedetto F., Del Ponte A., and Marinari S. Systemic effects of COPD. Respir Med 99 Suppl B (2005) S3-S10
30. Schols A.M., and Wouters E.F. Nutritional abnormalities and supplementation in chronic obstructive pulmonary disease. Clin Chest Med 21 (2000) 753-762
31. Ionescu A.A., and Schoon E. Osteoporosis in chronic obstructive pulmonary disease. Eur Respir J 22 Suppl 46 (2003) S64-S75
32. Andreas S., Ander S.D., Scanlon P.D., and Somers V.K. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest 128 (2005) 3618-3624
33. Van den Bemt L., Schermer T., Bor H., Smink R., Van Weel-Baumgarten E., Lucassen P., et al. The risk for depresion comorbidity in patients with COPD. Chest 135 (2009) 108-114
34. Xu W., Collet J.P., Shapiro S., Lin Y., Yang T., Platt R.W., et al. Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. Am J Respir Crit Care Med 178 (2008) 913-920